DVAX Stock Analysis: Buy, Sell, or Hold?
DVAX - Dynavax Technologies Corporation
$15.49
0.00 (0.03%)
▲
HOLD
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 19, 2026
17d
Get Alerted When DVAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: DVAX trades at premium valuation expecting 5.3% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: DVAX trades at premium valuation expecting 5.3% growth. Hold existing positions but don't chase. Wait for better entry.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$11.56
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$7.18
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: DVAX is currently trading at $15.48, which is considered fair relative to its 30-day fair value range of $14.04 to $16.33. From a valuation perspective, the stock is trading at a premium (Forward PE: 46.9) compared to its historical average (40.1). At these levels, the market is pricing in 5.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, DVAX is in a strong uptrend. The price is currently testing key support at $15.47. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: DVAX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $22.00 (+42.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, DVAX is in a strong uptrend. The price is currently testing key support at $15.47. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: DVAX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $22.00 (+42.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$14.04 -
$16.33
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
49.0%
Protect Your Profits
DVAX is technically overbought (RSI 76). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 42.1% below Wall St target ($22.00)
- NEUTRAL: Trading at premium valuation - market expects 5.3% growth which is achievable
Fair Price Analysis
30-Day Fair Range
$14.04 -
$16.33
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$15.47
Resistance Level
$15.69
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
46.92
Wall Street Target
$22.00
(+42.1%)
Revenue Growth (YoY)
17.7%
Earnings Growth (YoY)
69.3%
Profit Margin
-13.1%
Valuation Premium vs History
+5.3% premium
PE vs Historical
46.9 vs 40.1
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+5.3%
(market-implied from PE analysis)
1-Year Target
$16.31
(+5%)
2-Year Target
$17.17
(+11%)
3-Year Target
$18.08
(+17%)
3-Yr Target (if PE normalizes)
(PE: 47→40)
PE COMPRESSION
$15.45
(0%)
Earnings growth offset by PE compression
Last updated: February 01, 2026 4:54 AM ET
Data refreshes hourly during market hours. Next update: 5:54 AM
Data refreshes hourly during market hours. Next update: 5:54 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DVAX showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Scott Dunseth Myers
BUY
3800 shares
2025-08-22
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$179 | 62 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$158 | 56 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$84 | 57 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 57 HOLD |
Advanced DVAX Option Strategies
Professional options setups generated by AI based on today's DVAX price and gamma walls.
